Early test: can a drug duo help the immune system fight breast cancer?
NCT ID NCT02999477
Summary
This small, early-stage study tested a combination of chemotherapy (nab-paclitaxel) and an immunotherapy drug (pembrolizumab) as a treatment before surgery for a common type of breast cancer. The main goal was to see how this combination changed a specific marker (PD-L1) on the participants' tumors. Researchers enrolled 32 people with hormone-positive, HER2-negative breast cancer to learn how their bodies and tumors responded to the two-drug approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.